Spots Global Cancer Trial Database for primary central nervous system lymphoma
Every month we try and update this database with for primary central nervous system lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) | NCT04457869 | Primary Central... Secondary Centr... | F520 | 18 Years - | Shandong New Time Pharmaceutical Co., LTD | |
| Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma | NCT02113007 | Primary Central... | Rituximab plus ... | 18 Years - | SCRI Development Innovations, LLC | |
| Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients | NCT00863460 | Primary Central... | cranial radioth... intensive chemo... MTX based chemo... | 18 Years - 60 Years | Institut Curie | |
| Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma | NCT02313389 | Primary Central... | Rituximab, Meth... | 60 Years - | Assistance Publique - Hôpitaux de Paris | |
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | NCT05351593 | CNS Lymphoma Primary Central... Secondary Centr... | Tafasitamab Lenalidomide | 18 Years - | University of California, San Francisco | |
| Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | NCT02657785 | Primary Central... | R-IDARAM plus i... | 18 Years - 75 Years | Navy General Hospital, Beijing | |
| Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma | NCT05135858 | Primary Central... | Glucarpidase Methotrexate (M... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | NCT02836158 | Primary Central... | R-IDARAM plus i... | 60 Years - 75 Years | Navy General Hospital, Beijing | |
| Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute | NCT02655744 | Primary Central... | Standard treatm... | 18 Years - 84 Years | Chang Gung Memorial Hospital | |
| Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | NCT00003929 | Lymphoma | filgrastim lomustine procarbazine hy... radiation thera... | - | Case Comprehensive Cancer Center | |
| A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma | NCT04845139 | Refractory Cent... Relapsed Primar... Primary Central... | Nivolumab | 18 Years - 80 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | NCT05485753 | Primary Central... Secondary Centr... | GNC-038 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma | NCT05334238 | Primary Central... | Orelabrutinib | 18 Years - 65 Years | Ruijin Hospital | |
| Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma | NCT00712062 | Primary Central... | Pemetrexed | 18 Years - | University of Florida | |
| Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | NCT02836158 | Primary Central... | R-IDARAM plus i... | 60 Years - 75 Years | Navy General Hospital, Beijing | |
| Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma | NCT05347641 | Primary Central... | Penpulimab | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT01647971 | Non-Hodgkins Ly... B-cell Lymphoma Waldenstrom's M... Marginal Zone L... Chronic Lymphoc... Small Lymphocyt... Primary Central... | Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) | NCT02779101 | Primary Central... | pembrolizumab | 18 Years - | Medical University of Vienna | |
| Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | NCT04083066 | Primary Central... | rituximab in co... | 14 Years - 75 Years | Zhengzhou University | |
| A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) | NCT04457869 | Primary Central... Secondary Centr... | F520 | 18 Years - | Shandong New Time Pharmaceutical Co., LTD | |
| Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma | NCT05347641 | Primary Central... | Penpulimab | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL) | NCT04070040 | Primary Central... | Camrelizumab | 18 Years - | Beijing Sanbo Brain Hospital | |
| Chemotherapy, Filgrastim, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | NCT00003929 | Lymphoma | filgrastim lomustine procarbazine hy... radiation thera... | - | Case Comprehensive Cancer Center | |
| Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | NCT05390749 | Primary Central... | Orelabrutinib Pomalidomide Rituximab Methotrexate | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma | NCT02313389 | Primary Central... | Rituximab, Meth... | 60 Years - | Assistance Publique - Hôpitaux de Paris | |
| PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | NCT03120000 | Primary Central... | PQR309 | 18 Years - | PIQUR Therapeutics AG | |
| MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma | NCT02399189 | Primary Central... | R-MT followed b... | 18 Years - 65 Years | Peking University | |
| Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | NCT00003505 | Primary Central... | antineoplaston ... antineoplaston ... alternative pro... biological ther... biologically ba... cancer preventi... complementary a... differentiation... | 18 Years - | National Cancer Institute (NCI) | |
| Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma | NCT02203526 | Primary Central... | Isavuconazole TEDDI Rituximab Cytarabine TEDD Ibrutinib (Arms... Methotrexate Ibrutinib (Arm ... Ibrutinib (Arm ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) | NCT04457869 | Primary Central... Secondary Centr... | F520 | 18 Years - | Shandong New Time Pharmaceutical Co., LTD | |
| Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma | NCT04899427 | Primary Central... | orelabrutinib Sintilimab Tislelizumab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma | NCT02983942 | Primary Central... | ketogenic diet Routine diet | 18 Years - 70 Years | Beijing Tiantan Hospital | |
| Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma | NCT00074178 | Lymphoma | filgrastim pegfilgrastim cyclophosphamid... cytarabine dexamethasone etoposide phosp... methotrexate | 16 Years - 75 Years | OHSU Knight Cancer Institute | |
| A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL | NCT05036577 | Primary Central... | Orelabrutinib Rituximab Methotrexate (M... Dexamethasone | 18 Years - 75 Years | Huashan Hospital | |
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | NCT05351593 | CNS Lymphoma Primary Central... Secondary Centr... | Tafasitamab Lenalidomide | 18 Years - | University of California, San Francisco | |
| Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine | NCT00503594 | Lymphoma | Methotrexate an... Methotrexate , ... | 60 Years - | Assistance Publique - Hôpitaux de Paris | |
| Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases | NCT00276783 | Brain and Centr... Lymphoma Metastatic Canc... | pemetrexed | 18 Years - 120 Years | Northwestern University | |
| Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | NCT04462328 | Primary Central... | Durvalumab Acalabrutinib | 18 Years - | Washington University School of Medicine | |
| Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine | NCT00503594 | Lymphoma | Methotrexate an... Methotrexate , ... | 60 Years - | Assistance Publique - Hôpitaux de Paris | |
| Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma | NCT04514393 | Primary Central... PCNSL Non Hodgkin Lym... | Methotrexate Ibrutinib Temozolomide | 18 Years - 70 Years | Sun Yat-sen University | |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | NCT05681195 | Primary Central... Secondary Centr... Relapsed Cancer Refractory Canc... | Pemetrexed Zanubrutinib Autologous Stem... Whole Brain Rad... | 18 Years - | Baptist Health South Florida | |
| Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma | NCT04899427 | Primary Central... | orelabrutinib Sintilimab Tislelizumab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL | NCT04066920 | Primary Central... | IBER salvage ch... | 20 Years - 79 Years | Chonnam National University Hospital | |
| Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma | NCT00193973 | Primary Central... | Idarubicin, Met... Radiation Thera... | 18 Years - 70 Years | Trans Tasman Radiation Oncology Group | |
| MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma | NCT02399189 | Primary Central... | R-MT followed b... | 18 Years - 65 Years | Peking University | |
| PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | NCT02669511 | Primary Central... | PQR309 | 18 Years - | PIQUR Therapeutics AG | |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL | NCT04421560 | Primary Central... Recurrent Cance... Refractory Canc... Relapsed Cancer | Ibrutinib Pembrolizumab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL) | NCT04070040 | Primary Central... | Camrelizumab | 18 Years - | Beijing Sanbo Brain Hospital | |
| Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma | NCT04934579 | Primary Central... | Rituximab Lenalidomide Methotrexate | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | NCT05681195 | Primary Central... Secondary Centr... Relapsed Cancer Refractory Canc... | Pemetrexed Zanubrutinib Autologous Stem... Whole Brain Rad... | 18 Years - | Baptist Health South Florida | |
| Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma | NCT04737889 | Primary Central... | Rituximab Lenalidomide Methotrexate Temozolomide | 18 Years - 70 Years | Henan Cancer Hospital | |
| Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma | NCT00074191 | Lymphoma | cytarabine dexamethasone lomustine methotrexate procarbazine hy... | 16 Years - 75 Years | OHSU Knight Cancer Institute | |
| Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | NCT00003505 | Primary Central... | antineoplaston ... antineoplaston ... alternative pro... biological ther... biologically ba... cancer preventi... complementary a... differentiation... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment | NCT00544284 | Brain and Centr... Lymphoma Metastatic Canc... Unspecified Adu... | bortezomib temozolomide pharmacological... | 18 Years - | City of Hope Medical Center | |
| Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | NCT05390749 | Primary Central... | Orelabrutinib Pomalidomide Rituximab Methotrexate | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response | NCT06175000 | Primary Central... | Cognitive Asses... Obinutuzumab Quality of Life... | 18 Years - | Providence Health & Services | |
| A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | NCT04831658 | Primary Central... | the dose-escala... | 18 Years - 69 Years | Zhengzhou University | |
| Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute | NCT02655744 | Primary Central... | Standard treatm... | 18 Years - 84 Years | Chang Gung Memorial Hospital | |
| Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma | NCT05135858 | Primary Central... | Glucarpidase Methotrexate (M... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | NCT04831658 | Primary Central... | the dose-escala... | 18 Years - 69 Years | Zhengzhou University | |
| Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma | NCT04737889 | Primary Central... | Rituximab Lenalidomide Methotrexate Temozolomide | 18 Years - 70 Years | Henan Cancer Hospital | |
| BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT | NCT03733327 | Primary Central... Autologous Hema... Conditioning | Busulfan (BU) Cyclophosphamid... Etoposide (VP-1... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System | NCT03495960 | Primary Central... | Rituximab Methotrexate Procarbazine Lenalidomide Radiotherapy Temozolomide | 70 Years - | International Extranodal Lymphoma Study Group (IELSG) | |
| Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma | NCT05334238 | Primary Central... | Orelabrutinib | 18 Years - 65 Years | Ruijin Hospital | |
| Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | NCT04462328 | Primary Central... | Durvalumab Acalabrutinib | 18 Years - | Washington University School of Medicine | |
| Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma | NCT02983942 | Primary Central... | ketogenic diet Routine diet | 18 Years - 70 Years | Beijing Tiantan Hospital | |
| Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) | NCT02779101 | Primary Central... | pembrolizumab | 18 Years - | Medical University of Vienna | |
| A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma | NCT04845139 | Refractory Cent... Relapsed Primar... Primary Central... | Nivolumab | 18 Years - 80 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma | NCT04845139 | Refractory Cent... Relapsed Primar... Primary Central... | Nivolumab | 18 Years - 80 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) | NCT00153530 | Central Nervous... | methotrexate radiotherapy | 18 Years - | Charite University, Berlin, Germany |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
